Late Effects following Hematopoietic Cell Transplantation for Children  by Dahllöf, Göran et al.
Biology of Blood and Marrow Transplantation 14:88-93 (2008)
Q 2008 American Society for Blood and Marrow Transplantation
1083-8791/08/1401-0001$32.00/0
doi:10.1016/j.bbmt.2007.10.018Late Effects following Hematopoietic Cell
Transplantation for Children
G€oran Dahll€of,1 Sangeeta R. Hingorani,2 Jean E. Sanders3
1 Department of Pediatric Dentistry, Karolinska Institutet, Huddinge, Sweden; 2 Department of Pediatrics, University of
Washington School of Medicine, Seattle, Washington; and 3 Clinical Research Division, Fred Hutchinson Cancer
Research Center, Seattle, Washington
Correspondence and reprint requests: Goran Dahllof, DDS, PhD, Department of Pediatric Dentistry, Karolinska
Institutet, P.O. Box 4064, SE-141 04 Huddinge, Sweden (e-mail: Goran.Dahllof@ofa.ki.se).
High-dose chemotherapy or chemoradiotherapy followed by hematopoietic cell transplantation (HCT) is being
used for an ever increasing number of children with malignant or nonmalignant disorders, and improved results
are leading to an ever increasing number of long-term survivors. Understanding the delayed effects that may oc-
cur after HCT is important in determining the evaluations to perform for this unique group of patients. The ar-
ticles that follow detail what has been observed to date regarding the oral cavity and dental late effects, the kidney
after HCT, and the evaluations to perform to determine late effects when patients return to the centers after
their HCT.
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When considering the evaluations to perform, the
impact of the patient’s disease, the immunobiology of
transplantation, and the effects related to the trans-
plant preparative regimen, all must be considered.
EFFECTS RELATED TO THE DISEASE PROCESS
Rejection and Relapse
An important element to consider relates to the
underlying disease for which the transplant was per-
formed, and also determining whether the patient
has a graft. Late graft rejection almost never occurs
when the donor and recipient are HLA matched and
the transplant preparative regimen was a myeloablative
regimen. When donors are not HLA identical and/or
the preparative regimen was a reduced intensity or
nonmyeloablative regimen, late graft rejection has
been observed (suggested studies: Bone marrow exam-
ination for cellularity; Bone marrow cytogenetics;
peripheral blood chimerism).
Aside from performance of a bone marrow evalua-
tion to determine cellularity and cytogenetics, types of
cells present, and origin (donor or host) of the cells,
performance of peripheral blood chimerism studies is
important. The quantitation of donor engraftment is
performed using sex chromosome specific fluorescent88in situ hybridization probes for sex mismatched donors
or polymerase chain reaction (PCR)-based techniques
to detect donor-specific variable nucleotide tandem re-
peats sequences (VNTR). The studies should deter-
mine origin of CD31 cells and CD331 cells for all
patients as well as CD19, CD56, CD8, and CD4 for
some patients, such as those with immune deficiency
disorders.
Therapy
A uniform and successful approach to the problem
of graft rejection has not been developed. A second
transplant is usually tried using the same or different
HCT donor and often times using a different prepar-
ative regimen that contains additional immune sup-
pression.
When the transplant is performed for hematologic
malignancy, despite high doses of chemotherapy or
chemoradiotherapy, relapse does occur. The incidence
of relapse varies with the phase of disease at the time of
HCT. Between 15% and 40% of patients who receive
a transplant while in remission will relapse, whereas up
to 80% of those with advanced disease transplanted in
relapse will develop recurrent leukemia [1]. Most who
relapse do so within the first year after transplant, al-
though later relapses have occurred. Use of prophylac-
tic testicular radiotherapy during the preparative
regimen has almost completely prevented the develop-
ment of isolated testicular relapse among boys with
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planted for Ph1 disease (either ALL or chronic mye-
logenous leukemia (CML)) should have regular
follow-up with bcr/abl PCR studies to determine mo-
lecular relapse early [2,3]. Intervention may be neces-
sary depending on the underlying disease and the
PCR quantitation.
Therapy
A uniform approach to the patient who develops
recurrent leukemia has not been developed, but is
left to the individual investigator. A lot depends on
the length of time after HCT that relapse occurs and
the condition of the patient. Patients with acute leuke-
mia who respond to conventional remission induction
chemotherapy may be candidates for second transplant
providing a suitable second transplant preparative reg-
imen can be devised. An example is use of total body
irradiation (TBI) containing preparative regimen
when relapse occurred after busulfan (Bu) and cyclo-
phosphamide (Cy) initial preparative regimen [4].
However, a satisfactory second transplant preparative
regimen has not been determined for patients who re-
lapse after an initial transplant preparative regimen
containing TBI. Patients with Ph1 CML may do
well with Imatinib therapy.
EFFECTS RELATED TO THE TRANSPLANT
IMMUNOBIOLOGY
Chronic graft-versus-host disease (cGVHD) oc-
curs in 30% to 60% of patients, more often when the
donor is not an HLA-identical sibling and when there
is a history of acute GVHD (aGVHD). Recent studies
have shown that there is an increased risk of developing
cGVHD when growth factor-mobilized peripheral
blood stem cell (PBSC) grafts are used compared
to marrow grafts. cGVHD is also more likely when
the recipient or donor is older, is cytomegalovirus
(CMV) seropositive, or is a male patient who receives
HCT from a multiparous female donor. Risk factors
for mortality at the time of diagnosis of cGVHD
include a platelet count \100,000, .0.5 mg/kg/day
prednisone, elevated serum total bilirubin, older recip-
ient, prior aGVHD, and HLA mismatching [5].
cGVHD is defined by the presence of hallmark
cGVHD features that resemble autoimmune diseases,
including systemic sclerosis, Sjorgren syndrome,
biliary cirrhosis, runting syndrome, bronchiolitis
obliterans, immune cytopenias, and chronic immuno-
deficiency [6]. cGVHD requires the presence of at
least 1 diagnostic clinical sign of cGVHD or the pres-
ence of at least 1 distinctive manifestation confirmed
by pertinent biopsy or other relevant tests. The overall
severity of cGVHD is determined by a 0-3 point score
(none, mild, moderate, severe) that reflects the clinical
effect of cGVHD on the patient’s functional status.cGVHD frequently involves the skin, liver, eyes,
mouth, upper respiratory tract, and esophagus. Un-
controlled cGVHD interferes with immune reconsti-
tution, and is strongly associated with increased risks
of opportunistic infections.
Diagnosis and Classification
See Table 1.
Therapy
A complete discussion of therapy of cGVHD is be-
yond the scope of this article. In the absence of throm-
bocytopenia or steroid treatment at the onset of
cGVHD, patients assigned a mild global severity score
are managed with local or low-dose systemic immuno-
suppression, with no impact on survival [6]. This
means that systemic therapy is usually not given to pa-
tients with mild abnormalities of 1 or 2 organs that do
not cause functional impairment, jaundice, or marked
elevations of liver enzymes, or skin manifestations that
are not extensive. In contrast, involvement of 2 or more
organs, or moderate to severe abnormalities of a single
organ with functional impairment requires systemic
immunosuppression. Standard primary therapy for
clinical extensive cGVHD usually begins with gluco-
corticoids and extended administration of cyclospor-
ine or tacrolimus. After cGVHD manifestations have
been controlled by daily glucocorticoids (usually 14
days), tapering of glucocorticoids to alternate-day
schedule at the lowest possible dose can minimize ste-
roid-related side effects. The median duration of sys-
temic immunosuppression for the treatment of
cGVHD approximates 3 years after peripheral blood
stem cells (PBSC) allografts and 2 years after marrow
allografts. Approximately 20% of patients receiving
primary therapy for cGVHD develop recurrent malig-
nancy, and 10% die from causes other than recurrent
malignancy. The remaining 33% require secondary
treatment with a variety of other immunosuppressive
agents, and these patients tend to require prolonged
therapy. Risk factors for prolonged duration of sys-
temic immunosuppression includes receipt of PBSC,
male patients with female donors, multiple organ in-
volvement at onset of cGVHD, HLA mismatching,
and hyperbilirubinemia.
EFFECTS RELATED TO THE TRANSPLANT PREPARATIVE
REGIMEN
Endocrine System
Growth. Height growth results from the interac-
tion of genetics, nutrition, hormones, metabolism,
and cerebrocortical influences. In infancy, growth is
largely determined by nutrition and metabolic factors;
in childhood, growth is mainly influenced by growth
hormone (GH), and in puberty growth is largely influ-
enced by the synergistic action of GH and sex steroids.
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Organ/Site Diagnostic Common* Distinctive†
Skin Poikiloderma Erythema Dispigmentation
Lichen planus-like features Maculopapular rash
Sclerotic features
Morphia features
Nails Dystrophy
Longitudinal ridging
Nail loss
Scalp New onset alopecia
Scaling, papulosquamous lesions
Mouth Lichen-type features Gingivitis Xerostomia
Hyperkeratotic plaques Mucositis Mucocele
Restriction of mouth opening Erythema Mucosal atrophy
Pseudomenbranes
Ulcers
Eyes New onset dry, gritty, painful
Conjunctivitis
Keratoconjunctivitis sicca
Punctate keratopathy
GI tract Esophageal web Anorexia, nausea, vomiting,
diarrhea, failure to thrive
Esophageal strictures
Liver Bilirubin .2 ULN
Alk Phosp 2 ULN
AST/ALT.2 ULN
Lung Bronchiolitis obliterans
based on lung biopsy
Bronchiolitis obliterans based on PFT
and radiology
Muscles, fascia,
joints
Joint stiffness or contractures
secondary to sclerosis, Fasciitis
Myositis
Polymyositis
Modified from [6].
GI indicates gastrointestinal; cGVHD, chronic GVHD; aGVHD, acute GVHD.
*Seen in both aGVHD and cGVHD alone enough to establish a diagnosis of cGVHD.
†Seen in cGVHD but are insufficient alone to establish the diagnosis.Thus, GH has a major role in the height growth pro-
cess.
Several studies have suggested that patients who
receive chemotherapy preparative regimens without
having received cranial irradiation have height losses
that are less than that observed after TBI containing
preparative regimens [7,8]. Irradiation to the central
nervous system (CNS) has been associated with GH
deficiency that appears to be related to the child’s
age at the time of irradiation, the irradiation dose re-
ceived, and the length of time lapsed after completion
of the irradiation [9]. Children who have received cra-
nial irradiation prior to a TBI preparative regimen
have their total CNS irradiation dose exceed the esti-
mated threshold of 30 Gy for development of GH de-
ficiency [9]. GH deficiency may develop within 2-3
years after receiving this dose of CNS irradiation,
whereas GH deficiency may not develop in patients
who receive lower doses of CNS irradiation for up to
10 years.
Following preparative regimens with Cy only or
with Bu/Cy, in general, normal growth rates and
height standard deviation (SD) scores have beenobserved [10-12]. Growth impairment after TBI pre-
parative regimens has been well documented [13-16].
Patients who received CNS irradiation prior to TBI
had height SD scores that were less than those who
had not received CNS irradiation [17].
GH deficiency varies from 20% to 85%, depend-
ing upon differences in time of testing, differences in
preparative regimen received, inclusion of patients
with and without cranial irradiation, and use of differ-
ent methods of GH testing [18]. Even though GH de-
ficiency has been observed, less than half have received
GH therapy, often because of investigators feeling that
GH therapy did not benefit the children. Recent data
suggests that improvements in final height can be
achieved with contemporary dosing regimens that uti-
lize daily GH doses of 0.04 mg/kg increasing to 0.06
mg/kg at puberty [19]. One recent study shows that
when a group of GH deficient children transplanted
with fractionated TBI either received or did not re-
ceive GH therapy, final height was a function of age
at treatment and patient sex, with male patients
having the poorest growth [16]. Children treated at
\10 years of age had the best response to GH therapy
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stadiometer (annually); bone age (annually until
maturity); GH studies (annually until GH deficiency
determined).
Treatment
GH deficiency should be treated with GH therapy
until the patient reaches maturity. The administration
of the GH is best managed by a pediatric endocrinol-
ogist. The use of GH in adult patients remains
controversial.
Thyroid
Because normal thyroid hormone production is
needed for normal height growth, subnormal thyroid
hormone production contributes to decreased height
growth. Results from studies show that the majority
of patients prepared with chemotherapy-only prepara-
tive regimens have normal thyroid function. After irra-
diation the onset of thyroid dysfunction may begin as
compensated hypothyroidism with elevated thyroid
stimulating hormone (TSH) and normal thyroid hor-
mone levels, with some patients progressing on to
overt hypothyroidism [20]. Thyroid malignancy oc-
curs between 1.5 and 6.0 years after irradiation therapy
according to some reports, but others suggest a latency
period for up to 40 years, with a peak incidence be-
tween 15 and 25 years after irradiation [21]. Ultra-
sound detects thyroid abnormalities in 44% of
survivors of childhood cancer who receive irradiation
to the head and neck [22] (suggested studies: TSH,
T4 , free T4 , thyroid ultrasound—annually).
Therapy
All patients who develop overt hypothyroidism
should received treatment with thyroxin managed by
a pediatric endocrinologist.
Puberty
This phase of development is accompanied by sub-
stantial changes in gonadal and GH activity, develop-
ment of secondary sexual characteristics, and increased
growth velocity. Normally pubertal development is
closely related with osseous maturation measured by
bone age. The initiation and completion of puberty re-
quires an intact hypothalamic-pituitary-gonadal axis.
When the pubertal sex hormone secretion is absent,
the increased growth velocity associated with pubertal
growth spurt is blunted and development of secondary
sexual characteristics is delayed or absent. Children
with hypogonadotrophic hypogonadism have an ab-
sence of sex hormone production, delayed or absent
pubertal development, delayed pubertal growth spurt,
and a decrease in final adult height [23]. Children who
receive Cy only in the transplant preparative regimen
have normal pubertal development, but those whoreceive Bu/Cy preparative regimen have delayed de-
velopment. After fractionated TBI preparative regi-
mens, approximately half of the children develop
normally through puberty (suggested studies: Tanner
Developmental Score—annually after age 10 years;
LH and FSH gonadotropin levels; estradiol or testos-
terone levels).
Treatment
Children with evidence of gonadal failure and de-
layed pubertal development will likely benefit from
the use of supplemental sex hormone therapy adminis-
tered with the guidance of a pediatric endocrinologist.
Doses of sex hormone therapy should begin low, with
a gradual increase to simulate natural hormone pro-
duction and to prevent premature advancement of
bone age and to promote the pubertal growth spurt.
Patients with normal pubertal development, normal
gonadotropins, and sex hormone production should
receive appropriate sexual behavior counseling as
pregnancy could occur.
Diabetes Mellitus
Type 2 diabetes has been described as 1 of the late
effects of pediatric HCT [24-26]. Risk factors for de-
velopment of type 2 diabetes included patient diagno-
sis, as children, with leukemia are at greater risk than
patients with other underlying diagnoses, non-Cauca-
sian race, family history of diabetes, and having previ-
ous L-aspargainase toxicity [24]. In this large study
with a 30-year follow-up, hypertension and hyperlip-
idemia were present in 20% of evaluable patients, sug-
gesting the development of the insulin resistance
syndrome, also known as the metabolic syndrome
[27] (suggested studies: Fasting serum glucose).
Therapy
Management of patients with either type 1 or type
2 diabetes is best done by a pediatric endocrinologist.
Pulmonary Dysfunction
The therapy used in the transplant preparative reg-
imens may result in treatment-related pulmonary
complications. Some of the pulmonary complications
seen after HCT include pulmonary edema, idiopathic
pneumonia syndrome, diffuse alveolar hemorrhage,
infectious pneumonia, bronchiolitis obliterans (BO),
bronchiolitis obliterans with organizing pneumonia
(BOOP), and restrictive and obstructive lung disease
[28,29]. Longitudinal pediatric HCT patient studies
of pulmonary function have generally shown a decline
in lung volumes and diffusing capacity from pretrans-
plant to 3-6 months afterward, with partial recovery by
1-2 years followed by stable lung volumes up to 10
years [30-32]. One cross-sectional study showed
a 23% prevalence of restrictive impairment with no
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ing capacity abnormality [33]. Another large (N5 215)
pediatric patient cross-sectional study showed that
40% of patients had either restrictive lung disease
(RLD) (28%) or obstructive lung disease (OLD)
(9%) or both (3%), and at least 15% had isolated de-
creased diffusion capacity (DLCO). Risk factors for
RLD included TBI in the transplant preparative regi-
men, diagnosis of leukemia, scleroderma presence, and
autologous transplant [34]. In this same study the risk
factors for OLD included increasing time after trans-
plant (.20 years), cGVHD, fractionated TBI. This
study suggested that the pattern of low-DLCO may
be characteristic of pulmonary vascular disease, and
hence, late pulmonary hypertension may be more
common than previously recognized (suggested stud-
ies: Pulmonary function tests with DLCO annually
after age 6 years).
Treatment
All patients with abnormal pulmonary function
test results should be evaluated further to determine
the underlying etiology if possible.
Osteoporosis/Osteopenia
The attainment of sufficient peak bone mineral
mass during adolescence and early adulthood is an im-
portant determinant of long-term bone heath [35]. It is
of concern that almost half of the children after HCT
have reduced bone mineral density and are at high risk
for osteoporotic fractures [36]. The only study to re-
port bone mineral density (BMD) in children after
HCT using dual-energy X-ray absorptiometry
(DEXA) found that BMD in children was significantly
lower than in adults [37]. Bone loss results from im-
paired bone mineralization through disturbances of
calcium and vitamin D homeostasis, osteoblast, and
osteoclast function, and deficiencies in GH or gonadal
hormone secretion. Factors responsible for these dis-
turbances include chronic illness, glucocorticoid ther-
apy, TBI, and other cytotoxic agents given before
HCT [38-41]. The leading cause of reduced BMD af-
ter HCT is prolonged glucocorticoid therapy for
GVHD. The National Institutes of Health Consensus
recommendations for management of bone loss in
adults with cGVHD include intake of calcium and
vitamin D and therapy with sex hormones and/or
bisphosphonate. A recent study in children with
cGVHD has demonstrated the beneficial effect of
bisphosphonate therapy in the group as well [42] (sug-
gested studies: DEXA scan at 3 months and 12 months
and annually).
Therapy
Calcium, vitamin D, bisphosphonate therapy
monthly until BMD normalize (within 1 SD).SUMMARY
HCT is a life-saving procedure for an increasing
number of children. As an ever increasing number of
patients are surviving long term, late effects related
to the original disease, the transplant procedure, and
to the transplant preparative are emerging and impact-
ing the quality of life of these survivors. An awareness
of the potential sequelae is necessary to permit appro-
priate counseling of the patient before transplant and
also to anticipate and recognize the late effects when
they become apparent posttransplant. The evaluations
and treatment suggestions are just 1 way of approach-
ing and treating the problem that may be present. As
more experience is gained in this developing field,
changes in the incidence of and approaches to diagno-
sis and treatment of many of the individual problems is
likely to occur.
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